Characterization of CCX282-B, an Orally Bioavailable Antagonist of the CCR9 Chemokine Receptor, for Treatment of Inflammatory Bowel Disease

The chemokine system represents a diverse group of G protein-coupled receptors responsible for orchestrating cell recruitment under both homeostatic and inflammatory conditions. Chemokine receptor 9 (CCR9) is a chemokine receptor known to be central for migration of immune cells into the intestine. Its only ligand, CCL25, is expressed at the mucosal surface of the intestine and is known to be elevated in intestinal inflammation. To date, there are no reports of small-molecule antagonists targeting CCR9. We report, for the first time, the discovery of a small molecule, CCX282-B, which is an orally bioavailable, selective, and potent antagonist of human CCR9. CCX282-B inhibited CCR9-mediated Ca2+ mobilization and chemotaxis on Molt-4 cells with IC50 values of 5.4 and 3.4 nM, respectively. In the presence of 100% human serum, CCX282-B inhibited CCR9-mediated chemotaxis with an IC50 of 33 nM, and the addition of α1-acid glycoprotein did not affect its potency. CCX282-B inhibited chemotaxis of primary CCR9-expressing cells to CCL25 with an IC50 of 6.8 nM. CCX282-B was an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9 (CCR9A and CCR9B) with IC50 values of 2.8 and 2.6 nM, respectively. CCX282-B also inhibited mouse and rat CCR9-mediated chemotaxis. Inhibition of CCR9 with CCX282-B results in normalization of Crohn's disease such as histopathology associated with the TNFΔARE mice. Analysis of the plasma level of drug associated with this improvement provides an understanding of the pharmacokinetic/pharmacodynamic relationship for CCR9 antagonists in the treatment of intestinal inflammation.

[1]  Si-young Song,et al.  Retinoic acid imprints gut-homing specificity on T cells. , 2004, Immunity.

[2]  S W Binder,et al.  CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. , 2001, Gastroenterology.

[3]  K. Papadakis,et al.  Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. , 2008, Gastroenterology.

[4]  Chuang Lu,et al.  Quantitative Prediction and Clinical Observation of a CYP3A Inhibitor-Based Drug-Drug Interactions with MLN3897, a Potent C-C Chemokine Receptor-1 Antagonist , 2010, Journal of Pharmacology and Experimental Therapeutics.

[5]  P. Board,et al.  α1Acid glycoprotein expression in human leukocytes: Possible correlation between α1-acid glycoprotein and inflammatory cytokines in rheumatoid arthritis , 1993, Inflammation.

[6]  S. Curbishley,et al.  Hepatic Endothelial CCL25 Mediates the Recruitment of CCR9+ Gut-homing Lymphocytes to the Liver in Primary Sclerosing Cholangitis , 2004, The Journal of experimental medicine.

[7]  T. O’Toole,et al.  Lymph Node Stromal Cells Support Dendritic Cell-Induced Gut-Homing of T Cells1 , 2009, The Journal of Immunology.

[8]  R. Scolyer,et al.  Activation of CCR9/CCL25 in Cutaneous Melanoma Mediates Preferential Metastasis to the Small Intestine , 2008, Clinical Cancer Research.

[9]  G. Kollias,et al.  Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. , 1999, Immunity.

[10]  A. Neish,et al.  REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY Microbes in Gastrointestinal Health and Disease , 2009 .

[11]  F. Annunziato,et al.  Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. , 1997, The American journal of pathology.

[12]  Stuart B. Goodman,et al.  Lymphocyte Cc Chemokine Receptor 9 and Epithelial Thymus-Expressed Chemokine (Teck) Expression Distinguish the Small Intestinal Immune Compartment , 2000, The Journal of experimental medicine.

[13]  J. Curtis,et al.  Effect of C-C chemokine receptor 2 (CCR2) knockout on type-2 (schistosomal antigen-elicited) pulmonary granuloma formation: analysis of cellular recruitment and cytokine responses. , 1999, The American journal of pathology.

[14]  K. Ley,et al.  GASTROENTEROLOGY 2006;131:1518–1529 Antibody Blockade of CCL25/CCR9 Ameliorates Early but not Late Chronic , 2022 .

[15]  N. Hosoe,et al.  Demonstration of functional role of TECK/CCL25 in T lymphocyte-endothelium interaction in inflamed and uninflamed intestinal mucosa. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[16]  Marie Malissen,et al.  The chemokine TECK is expressed by thymic and intestinal epithelial cells and attracts double‐ and single‐positive thymocytes expressing the TECK receptor CCR9 , 2000, European journal of immunology.

[17]  J. Jahnsen,et al.  Reduced chemokine receptor 9 on intraepithelial lymphocytes in celiac disease suggests persistent epithelial activation. , 2007, Gastroenterology.

[18]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[19]  T. Schall,et al.  392 PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease , 2009 .

[20]  James J. Campbell,et al.  Impaired Accumulation of Antigen-Specific CD8 Lymphocytes in Chemokine CCL25-Deficient Intestinal Epithelium and Lamina Propria1 , 2007, The Journal of Immunology.

[21]  E. Kremmer,et al.  CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine , 2007, Proceedings of the National Academy of Sciences.

[22]  K. Peden,et al.  CCR9A and CCR9B: Two Receptors for the Chemokine CCL25/TECK/Ckβ-15 That Differ in Their Sensitivities to Ligand , 2000, The Journal of Immunology.

[23]  Yu Wang,et al.  Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell- and T Cell-Active Chemokines Including ELC, SLC, and TECK , 2000, The Journal of Immunology.

[24]  S. Targan,et al.  The Role of Thymus-Expressed Chemokine and Its Receptor CCR9 on Lymphocytes in the Regional Specialization of the Mucosal Immune System1 , 2000, The Journal of Immunology.

[25]  Junliang Pan,et al.  DCs metabolize sunlight-induced vitamin D3 to 'program' T cell attraction to the epidermal chemokine CCL27 , 2007, Nature Immunology.

[26]  A. Viola,et al.  Chemokines and their receptors: drug targets in immunity and inflammation. , 2008, Annual review of pharmacology and toxicology.

[27]  M. Nussenzweig,et al.  Mice lacking the CCR9 CC-chemokine receptor show a mild impairment of early T- and B-cell development and a reduction in T-cell receptor γδ+ gut intraepithelial lymphocytes , 2001 .

[28]  D. Schadendorf,et al.  Functional CCR9 expression is associated with small intestinal metastasis. , 2004, The Journal of investigative dermatology.

[29]  James J. Campbell,et al.  Human G Protein–Coupled Receptor Gpr-9-6/Cc Chemokine Receptor 9 Is Selectively Expressed on Intestinal Homing T Lymphocytes, Mucosal Lymphocytes, and Thymocytes and Is Required for Thymus-Expressed Chemokine–Mediated Chemotaxis , 1999, The Journal of experimental medicine.

[30]  S. Targan,et al.  Phenotype and Effector Function of CC Chemokine Receptor 9-Expressing Lymphocytes in Small Intestinal Crohn’s Disease1 , 2007, The Journal of Immunology.

[31]  Á. Zaballos,et al.  Cutting edge: identification of the orphan chemokine receptor GPR-9-6 as CCR9, the receptor for the chemokine TECK. , 1999, Journal of immunology.

[32]  B. Müller-Myhsok,et al.  Role of the novel Th17 cytokine IL‐17F in inflammatory bowel disease (IBD): Upregulated colonic IL‐17F expression in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD , 2008, Inflammatory bowel diseases.